Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
J Vasc Interv Radiol. 2022 Aug;33(8):949-955. doi: 10.1016/j.jvir.2022.05.002. Epub 2022 May 13.
To characterize the safety, tolerability, and efficacy of chemoembolization using drug-eluting embolic (DEE) microspheres in patients with recurrent and advanced head and neck cancer.
In this retrospective study, 32 patients (mean age, 57.2 years ± 2.8; 17 women) with recurrent (n = 16) and advanced (n = 16) head and neck cancer were treated with chemoembolization using DEE microspheres loaded with doxorubicin. Treatment response, overall survival, local progression-free survival, and adverse events were evaluated.
At 6 months after the procedure, the objective response and disease control rates were 25% and 69%, respectively. The median overall survival and local progression-free survival were 14.5 and 13.6 months, respectively. Seven (22%) patients experienced adverse events after the chemoembolization procedure. All the adverse events were related to postembolization syndrome, including vomiting and nausea (n = 1), pyrexia (n = 2), and localized pain (n = 7). No severe adverse events or procedure-related deaths were observed.
Chemoembolization using DEE microspheres was safe and tolerable in patients with recurrent and advanced head and neck cancer.
研究载多柔比星的药物洗脱微球栓塞化疗（DEE）治疗复发性和晚期头颈部肿瘤的安全性、耐受性和疗效。
本回顾性研究共纳入 32 例复发性（n=16）和晚期（n=16）头颈部肿瘤患者，平均年龄 57.2±2.8 岁，其中 17 例为女性。所有患者均接受 DEE 微球载多柔比星化疗栓塞治疗。评估治疗反应、总生存期、局部无进展生存期和不良事件。
治疗后 6 个月，客观缓解率和疾病控制率分别为 25%和 69%。中位总生存期和局部无进展生存期分别为 14.5 个月和 13.6 个月。7 例（22%）患者在化疗栓塞后出现不良事件。所有不良事件均与栓塞后综合征有关，包括呕吐和恶心（n=1）、发热（n=2）和局部疼痛（n=7）。未观察到严重不良事件或与治疗相关的死亡。
载多柔比星的 DEE 微球栓塞化疗治疗复发性和晚期头颈部肿瘤安全且耐受良好。
